Erasca investors face August 10 lead plaintiff deadline after 53.9% stock plunge
A securities class action alleges Erasca misled investors about ERAS-0015 comparisons and related risks, with investors who bought shares during the class period facing an August 10, 2026 deadline to seek lead plaintiff status.
Erasca, Inc. investors who bought during the January 14, 2025 to April 26, 2026 class period have until August 10, 2026 to seek appointment as lead plaintiff in a pending securities class action. The complaint alleges Erasca and certain top executive officers made materially false or misleading statements about ERAS-0015, including allegedly improper preclinical comparisons to Revolution Medicines, Inc. that exposed the company to patent and trade secret risk. The filing says the claims began to unravel on April 27, 2026, when Erasca disclosed a letter from Revolution Medicines asserting patent infringement and alleged trade secret misappropriation, sending the stock down nearly 11%, and then after market close the same day when Erasca reported preliminary Phase I data, disclosed that a patient who received 24 mg of ERAS-0015 had died about one month after starting treatment, and cautioned that product comparisons were based on cross-study analyses rather than head-to-head clinical trials. According to the complaint, those disclosures drove a further share decline of more than 48%.
- lead plaintiff: The investor appointed by the court to represent the proposed class and help direct the litigation.
- cross-study analyses: Comparisons made across separate studies rather than within a single head-to-head trial, which can limit how directly results can be compared.
- trade secret misappropriation: The alleged improper use or disclosure of confidential business information that derives value from remaining secret.